Bev has obtained European (EU) approval for EOC pts treated in fl on 12/2011. This study addresses the question of how Bev is used in routine practice for the fl treatment of OC pts.
102 centers were selected to be representative of the distribution of OC pts in France. All consecutive OC pts treated in fl in each center were screened in order to include at least 500 pts who gave their consent to participate to the ENCOURAGE cohort evaluating the long term Bev use in routine practice. We report here how Bev was prescribed in this series of pts.
From 04/2013 to 02/2015, 1158 evaluable pts representing 15% of French incidence cases were screened in academic hospital (15%), cancer center (29%), general hospital (25%), private center (31%). Bev was administered in 557 (48%) pts and mostly according to the label: with carboplatin (99%) and paclitaxel (98%), for stage IIIB-IV (97%), and at a dose of 15mg/kg (80.2%). Bev was NOT prescribed in 601/1158 pts and reasons were specified for 487pts. These were comorbidity including age over 70 (29%), neo-adjuvant strategy (22%), early stage (20%), inclusion in a trial (13%), no macroscopic residue after initial surgery (11%), early disease progression or death (3%), patient refusal (2%). Interestingly, in this series of 1158 consecutive pts, only about 1/3 of pts with comorbidity/age over 70, or no residue after initial surgery or treated with a neo-adjuvant strategy were excluded from Bev treatment, reflecting the heterogeneity of practice among centers.
Bev was administered in 1st line EOC treatment according to the EU label for the great majority of pts . However, the large variability of Bev prescription when patients had comorbidity, age over 70 or were treated with a neo-adjuvant strategy reflects the need of OC trials focusing on these populations of patients.
Clinical trial identification
Legal entity responsible for the study
J-L. Mouysset: Roche, Astellas, Sanofi, Janssen, Hospira, Novartis, Sandoz, Pierre Fabre. All other authors have declared no conflicts of interest.